Literature DB >> 29858791

Imaging T Cell Dynamics and Function Using PET and Human Nuclear Reporter Genes.

Jason T Lee1, Maxim A Moroz1, Vladimir Ponomarev2.   

Abstract

Adoptive cell transfer immunotherapy has demonstrated significant promise in the treatment of cancer, with long-term, durable responses. T cells expressing T cell receptors (TCRs) that recognize tumor antigens, or engineered with chimeric antigen receptors (CARs) can recognize and eliminate tumor cells even in advanced disease. Positron emission tomography (PET) imaging with nuclear reporter genes, a noninvasive method to track and monitor function of engineered cells in vivo, allows quantitative, longitudinal monitoring of these cells, including their expansion/contraction, migration, retention at target and off-target sites, and biological state. As an additional advantage, some reporter genes also exhibit "suicide potential" permitting the safe elimination of adoptively transferred T cells in instances of adverse reaction to therapy. Here, we describe the production of human nuclear reporter gene-expressing T cells and noninvasive PET imaging to monitor their cell fate in vivo.

Entities:  

Keywords:  Chimeric antigen receptors; Human nuclear reporter gene; Immunotherapy; Nucleoside kinases; PET; Reporter probe; T cell

Mesh:

Substances:

Year:  2018        PMID: 29858791      PMCID: PMC9344925          DOI: 10.1007/978-1-4939-7860-1_13

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  30 in total

Review 1.  Issues in the manufacture and transplantation of genetically modified hematopoietic stem cells.

Authors:  M Sadelain; F Frassoni; I Rivière
Journal:  Curr Opin Hematol       Date:  2000-11       Impact factor: 3.284

2.  AMIDE: a free software tool for multimodality medical image analysis.

Authors:  Andreas Markus Loening; Sanjiv Sam Gambhir
Journal:  Mol Imaging       Date:  2003-07       Impact factor: 4.488

3.  Understanding the standardized uptake value, its methods, and implications for usage.

Authors:  Joseph A Thie
Journal:  J Nucl Med       Date:  2004-09       Impact factor: 10.057

Review 4.  Assessing T lymphocyte function and differentiation by genetically encoded reporter systems.

Authors:  Mirjam E Hoekstra; Feline E Dijkgraaf; Ton N Schumacher; Jan C Rohr
Journal:  Trends Immunol       Date:  2015-06-10       Impact factor: 16.687

5.  Imaging TCR-dependent NFAT-mediated T-cell activation with positron emission tomography in vivo.

Authors:  V Ponomarev; M Doubrovin; C Lyddane; T Beresten; J Balatoni; W Bornman; R Finn; T Akhurst; S Larson; R Blasberg; M Sadelain; J G Tjuvajev
Journal:  Neoplasia       Date:  2001 Nov-Dec       Impact factor: 5.715

Review 6.  T-cell engineering for cancer immunotherapy.

Authors:  Michel Sadelain
Journal:  Cancer J       Date:  2009 Nov-Dec       Impact factor: 3.360

Review 7.  Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.

Authors:  Marc Cartellieri; Michael Bachmann; Anja Feldmann; Claudia Bippes; Slava Stamova; Rebekka Wehner; Achim Temme; Marc Schmitz
Journal:  J Biomed Biotechnol       Date:  2010-05-05

Review 8.  CAR therapy: the CD19 paradigm.

Authors:  Michel Sadelain
Journal:  J Clin Invest       Date:  2015-09-01       Impact factor: 14.808

9.  Noninvasive imaging of cell-mediated therapy for treatment of cancer.

Authors:  Elizabeth J Akins; Purnima Dubey
Journal:  J Nucl Med       Date:  2008-06       Impact factor: 10.057

10.  Quantitative PET reporter gene imaging of CD8+ T cells specific for a melanoma-expressed self-antigen.

Authors:  Chengyi J Shu; Caius G Radu; Stephanie M Shelly; Dan D Vo; Robert Prins; Antoni Ribas; Michael E Phelps; Owen N Witte
Journal:  Int Immunol       Date:  2008-12-23       Impact factor: 4.823

View more
  1 in total

1.  18F-FHBG PET-CT Reporter Gene Imaging of Adoptive CIK Cell Transfer Immunotherapy for Breast Cancer in a Mouse Model.

Authors:  Xiaofeng Li; Guotao Yin; Wei Ji; Jianjing Liu; Yufan Zhang; Jian Wang; Xiang Zhu; Lei Zhu; Dong Dai; Wenchao Ma; Wengui Xu
Journal:  Onco Targets Ther       Date:  2020-11-13       Impact factor: 4.147

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.